肥胖是一个独立的预后因素,减少了可手术的乳腺癌患者的病理完整反应
Murad Guliyev1, Özkan Alan1, Murat Günaltılı1
1Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul 34098, Turkey.
Medicina (Kaunas, Lithuania)
|January 8, 2025
概括
肥胖对接受新辅助化疗 (NACT) 的乳腺癌 (BC) 患者实现病理完整反应 (pCR) 有负面影响. 肥胖患者的pCR率显著降低,表明肥胖是治疗成功的负面预测因素.
科学领域:
- 在瘤学瘤学.
- 代谢综合征是代谢综合征的一种.
背景情况:
- 肥胖是已知的乳腺癌 (BC) 发展和更差的结果的风险因素.
- 在新辅助化疗 (NACT) 后,病理完整反应 (pCR) 与BC患者的长期预后改善有关.
研究的目的:
- 研究肥胖对在可手术的乳腺癌患者中获得PCR的预测效应,这些患者接受了NACT治疗.
- 为了比较肥胖 (BMI ≥30 kg/m2) 和非肥胖 (BMI <30 kg/m2) 患者之间的pCR率.
主要方法:
- 一个单一中心的回顾性研究,对191名女性患者进行了可手术的BC.
- 根据化疗前的BMI,患者被分为肥胖和非肥胖的组.
- 组之间的NACT病理反应的比较,根据组织学和更年期状态对子组进行分析.
主要成果:
- 肥胖患者 (43.4%) 与非肥胖患者 (45%,p=0.03) 相比,pCR率显著降低 (30%).
- 肥胖患者中较低的PCR率在HR-阳性/HER2-阴性亚型 (11%对27%,p=0.05) 和绝经后妇女 (29%对52%,p=0.03) 中显著.
- 肥胖 (OR:0.52) 和低Ki-67分数是PCR的独立负面预测因素.
结论:
- 肥胖是一种独立显著的负预测因素,用于在接受NACT的乳腺癌患者中实现pCR.
- 这些发现表明,肥胖会影响治疗反应,特别是在特定的患者亚组中.
- 需要进一步的研究,以了解肥胖对NACT结果的机制和临床影响.
相关概念视频
Obesity
372
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
372
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328


